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In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with
disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS-9450
has a potential for altering the course of the liver disease. In this phase 2, double-blind
study, 124 subjects with biopsy-proven NASH were randomized to once-daily placebo or 1,
5, 10, or 40 mg GS-9450 for 4 weeks. Absolute and percent changes from baseline in ALT
levels, AST levels, and caspase-3–cleaved cytokeratin (CK)-18 fragments at week 4 were
assessed by an analysis of covariance model with adjustment for baseline values. In the 40-
mg group, mean (SD) ALT decreased by 47 (43) U/L from baseline to week 4 (P < 0.0001
versus placebo), and the proportion of subjects with normal ALT increased from 0% to
35% at week 4. In the 40-mg group, mean AST decreased by 13 U/L from baseline (not sig-
niﬁcant), and the proportion with normal AST increased from 20% at baseline to 48% at
week 4. By week 4, mean CK-18 fragment levels had decreased to 393 (723) U/L in the GS-
9450 10-mg group and 125 (212) U/L in the 40-mg group, but these reductions were not
statistically signiﬁcant. No serious adverse events were reported during treatment, and the
percentage of subjects with at least one treatment-emergent grade 3 or 4 laboratory abnor-
mality ranged from 11.5% to 17% across the GS-9450 treatment groups versus 35% in the
placebo group. Conclusion: GS-9450 treatment induced signiﬁcant reductions in ALT levels
in NASH patients. Reductions in CK-18 fragment levels also occurred, although they were
not statistically signiﬁcant. At appropriate therapeutic indices, selective caspase inhibitors
may be a promising treatment option in patients with NASH. (HEPATOLOGY 2012;55:419-428)
C
urrent pharmacological options for nonalco-
holic steatohepatitis (NASH) are limited
because the mechanisms that trigger hepatic
inﬂammation in the steatotic liver are not well under-
stood. Inﬂammation is a major feature underlying the
progression between steatosis and steatohepatitis, and
clinical and experimental data have documented
increased hepatocyte apoptosis in patients with NASH.
Although apoptosis is a vital component of normal cel-
lular turnover and development, excessive apoptosis,
such as can occur in response to noxious stimuli, pro-
motes inﬂammation.1 Apoptosis leads to inﬂammation
either directly by activation of nuclear factor-jB (NF-
jB) with subsequent up-regulation of proinﬂammatory
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cytokines or indirectly by inducing adhesion mole-
cules, chemokines, and inﬂammatory cell recruitment.2
Moreover, clearance of apoptotic bodies elicits injuri-
ous inﬂammatory responses, which result in tissue
damage and promotion of ﬁbrosis.3
Both the extrinsic and the intrinsic (endogenous)
pathways of apoptosis are activated in experimental
models of NASH.1,4 NASH is characterized by a dysre-
gulated delivery of free fatty acids to the liver because of
impaired insulin sensitivity. Free fatty acids induce lip-
oapoptosis in many cell types, including hepatocytes.
Free fatty acids can activate the lysosomal pathway of
cell death5 and sensitize hepatocytes to tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis.6 Moreover, steatotic livers are sensi-
tized to Fas- and TRAIL-mediated apoptosis.7,8 Hepa-
tocyte apoptosis is increased in patients with NASH
and correlates with disease severity and stage of ﬁbrosis,
thus suggesting a pathogenic role for apoptosis in the
progression of the disease.9 Death receptor expression,
especially Fas and TNF receptor-1 (TNF-R1), is signiﬁ-
cantly enhanced in patients with NASH.9
Because apoptosis is a critical mediator of inﬂamma-
tion and ﬁbrosis in liver disease, inhibiting apoptosis may
theoretically be a useful therapeutic approach. Therefore,
oral, small-molecule antiapoptotic agents have been
developed. GS-9450 is a caspase inhibitor with selective
activity against caspases 1, 8, and 9. Caspase-8 is a key
initiating caspase essential for apoptosis induced by all
three death receptors (Fas, TNF-R1, and TRAIL recep-
tors 1 and 2).10 Short-term treatment with GS-9450 can
cause reductions in alanine aminotransferase (ALT) levels
in patients with chronic hepatitis C virus (HCV) infec-
tion,11 which is also accompanied by increased hepato-
cyte apoptosis. Given the potential for GS-9450 in treat-
ing apoptosis-mediated liver injury, we sought to evaluate
the safety and activity of GS-9450 in a proof-of-concept,
4-week pilot trial in subjects with NASH.
Subjects and Methods
Subjects
Eligible subjects were adults 18-75 years of age with
ALT > 60 U/L (as measured at a central laboratory), a
fatty liver as judged by ultrasound, and biopsy ﬁndings
consistent with NASH without evidence of cirrhosis.
The liver biopsy was required during screening if none
had been performed in the previous 12 months. The
histological diagnosis of NASH was made by the local
pathologist, without a central reading, and was based
on the presence of steatosis (>5% of hepatocytes con-
taining liver fat), hepatocyte ballooning, and lobular
inﬂammation, regardless of the amount of ﬁbrosis.
Subjects were required to have a platelet count
 75,000/mm3, absolute neutrophil count  1500/
mm3, hemoglobin  11.0 g/dL, and creatinine clear-
ance  70 mL/min as calculated with the Cockcroft-
Gault equation. Subjects with non–insulin-dependent
diabetes for < 10 years were eligible if the diabetes
had been managed with non-glitazone medications for
at least 6 months before screening. Subjects who had
either received glitazone treatment within 6 months of
screening or had peripheral diabetic neuropathy or
gastroparesis were not eligible.
Subjects were required to have a stable weight (i.e.,
no weight loss > 4%) for 8 weeks before screening
and to maintain consistent diet, food intake, and phys-
ical exercise during the study. Subjects with any other
cause of liver disease (e.g., viral hepatitis, autoimmune
hepatitis, hemochromatosis, and others) were excluded,
as were subjects with hepatocellular carcinoma (HCC).
Subjects were not included if their daily alcohol con-
sumption was higher than 30 g in males and 20 g in
females. Subjects with drug-induced or other forms of
secondary NASH were also excluded. All subjects pro-
vided written informed consent before undertaking
any study-related procedures.
Study Design
This was a Phase 2, randomized, double-blind, par-
allel-group, placebo-controlled, multicenter, interna-
tional study investigating the safety, tolerability, and
activity of multiple oral doses of GS-9450 in adults
with NASH. Qualifying subjects were stratiﬁed by the
presence or absence of type 2 diabetes (i.e., on or off
oral diabetic medication at study entry) and by geo-
graphic region. After stratiﬁcation, subjects were ran-
domly assigned (1:1:1:1:1) to one of ﬁve parallel
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treatment groups: placebo or GS-9450 1 mg, 5 mg,
10 mg, or 40 mg administered orally once daily for 4
weeks. On completion of treatment, subjects entered a
4-week follow-up period.
Because of the exploratory nature of this study, no
formal power or sample size calculations were used to
determine sample size. The number of subjects per
treatment arm was chosen empirically based on experi-
ence with change in ALT in previous studies (Support-
ing Table 1).
Before study initiation, each institution’s Independ-
ent Ethics Committee or Institutional Review Board
reviewed and approved the study. During the study, all
available safety and tolerability data were reviewed by
an independent Data Monitoring Committee.
Efﬁcacy Assessments
Serum ALT and AST Values. Absolute and percent
change from baseline in ALT and aspartate aminotrans-
ferase (AST) were evaluated on day 3, at weeks 1, 2,
3, and 4 of the on-treatment period, and at weeks 1,
2, 3, and 4 of the follow-up period. Percent of subjects
achieving ALT and AST normalization at various time
points was also evaluated. Normal levels were deﬁned
as follows: 43 U/L ALT and 36 U/L AST for males,
and 34 U/L ALT and 34 U/L AST for females.
Cytokeratin-18 Fragments. Blood samples were col-
lected at the week-2 and week-4 study visits for analysis
of serum caspase-3–cleaved cytokeratin (CK)-18 frag-
ments. CK-18 fragments were measured using the
M30-Apoptosense enzyme-linked immunosorbent assay
(ELISA) kit (Peviva AB, Stockholm, Sweden) in assays
conducted by Esoterix, Inc. (LabCorp; Austin, TX).
Pharmacokinetic Assessments
Concentrations of GS-9450 were determined in
plasma by using a validated bioanalytical assay. Steady-
state plasma pharmacokinetic parameters of GS-9450
assessed during weeks 2-4 included maximum observed
concentration of drug in plasma (Cmax), time of Cmax
(Tmax), half-life (T1/2), and area under the plasma con-
centration versus time curve over the dosing interval
(AUCtau). Trough concentrations were determined
from samples collected during treatment visits at weeks
1, 2, 3, and 4 and at the follow-up week-1 visit.
Safety Assessments
Safety was evaluated by assessment of clinical labora-
tory tests, physical examinations, vital signs measure-
ments, 12-lead electrocardiograms, and documentation
of adverse events (AEs). Fatigue was self-reported with-
out the use of a speciﬁc symptom score. Concomitant
medication intake was also recorded. All safety labora-
tory measurements were performed by Covance
Central Laboratory Services (Indianapolis, IN).
Endpoints and Statistical Analyses
The primary efﬁcacy endpoints were the absolute
and percent changes from baseline in ALT levels, AST
levels, and CK-18 fragment levels at week 4.
The primary analysis set for efﬁcacy included all
randomized subjects who received at least one dose of
study drug. Absolute and percent change from baseline
in ALT levels, AST levels, and CK-18 fragment levels
at week 4 were assessed by an analysis of covariance
(ANCOVA) model with adjustment for baseline
values. For pairwise treatment comparison involving
placebo, GS-9450 40 mg was compared ﬁrst. The
GS-9450 10-mg, 5-mg, and 1-mg pairwise compari-
sons with placebo were then considered sequentially to
minimize the family-wise type I error. P values and
95% conﬁdence intervals around the treatment group
differences were calculated. As an exploratory analysis,
the linear relationship between the percent measurable
change from baseline for ALT at weeks 2, 3, and 4 ver-
sus dose at week 4 was evaluated.
The pharmacokinetic analysis set included all subjects
who had evaluable pharmacokinetic proﬁles. Plasma con-
centration–time data for each subject were analyzed using
standard noncompartmental methods to compute phar-
macokinetic parameters. The primary method for evaluat-
ing dose proportionality was based on AUCtau and Cmax
using a power model that was ﬁtted using all fasted doses.
To explore GS-9450 exposure–response relationships,
standard pharmacodynamic models (e.g., inhibitory Emax,
inhibitory sigmoid Emax, linear) were ﬁt to the time-
weighted average change in CK-18 fragments and ALT
from baseline to week 4 and the corresponding AUCtau
and Cmax values for all subjects. Modeling was performed
using WinNonlin (version 5.2; Pharsight Corp., Moun-
tain View, CA); model discrimination was performed by
comparing Akaike Information Criteria, attainment of
reasonable parameter estimates, and reproducibility of pa-
rameter estimate outputs, given variable initial conditions.
The safety analysis set included all randomized sub-
jects who received at least one dose of study drug.
Safety data were summarized by incidence of treat-
ment-emergent AEs and laboratory abnormalities or
descriptive statistical summaries.
Results
Subject Population
Between September 2008 and August 2009, 254
subjects were screened and 124 subjects were
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randomized, treated, and completed study procedures
at 41 study sites, including 35 in the United States
and 6 in France (Fig. 1). The most common reason
for screening failure was ALT level below 60 IU/L (n
¼ 90). Subjects were predominantly male (70%), and
the majority (85%) were white (Table 1). At screening,
across the treatment groups, mean ALT levels ranged
from 94 to 109 U/L, and creatinine clearance ranged
from 92 to 102 mL/min. The majority of subjects
(84%) did not have type 2 diabetes. All groups had
comparable baseline body mass index (BMI), insulin
resistance surrogate markers (homeostasis model of
insulin resistance [HOMA-IR] in nondiabetics), and
aminotransferase values. All subjects had biopsy ﬁnd-
ings consistent with steatohepatitis as judged by a local
pathologist, and no subjects had cirrhosis. A minority
(n ¼ 16, 13%) had advanced ﬁbrosis. Nonalcoholic
fatty liver disease activity scoring (NAS) by central pa-
thologist overread was not employed for this short-
term, 4-week study.
Efﬁcacy Assessments
ALT. At week 4, reductions in ALT levels were
greater in GS-9450 treatment groups than placebo,
with mean (SD) changes from baseline ranging from
14 (40) to 47 (43) U/L in the GS-9450 groups
Fig. 1. Subject disposition throughout the study.
Table 1. Subject Demographic and Baseline Disease Characteristics
Characteristic GS-9450 1 mg (n ¼ 26) 5 mg (n ¼ 26) 10 mg (n ¼ 24) 40 mg (n ¼ 25) Placebo (n ¼ 23)
Male sex, no. (%) 19 (73) 21 (81) 13 (54) 17 (68) 17 (74)
Ethnicity, no. (%)a
Non-Hispanic/Latino 22 (85) 19 (73) 18 (75) 19 (76) 18 (78)
Hispanic/Latino 4 (15) 7 (27) 6 (25) 5 (20) 5 (21)
Race, no. (%)
White 20 (77) 21 (81) 24 (100) 23 (92) 18 (78)
Asian 3 (12) 2 (8) 0 1 (4) 2 (9)
American Indian or Alaska Native 0 1 (4) 0 0 1 (4)
Black or African-American 0 0 0 1 (4) 1 (4)
Other 3 (12) 2 (8) 0 0 1 (4)
Type 2 diabetes status, no. (%)
Absent 22 (85) 22 (85) 20 (83) 22 (88) 18 (78)
Present 4 (15) 4 (15) 4 (17) 3 (12) 5 (22)
Median (Q1, Q3) values
Age, years 49 (35, 53) 48 (38, 53) 45 (33, 55) 44 (31, 51) 51 (42, 59)
Weight, kg 98 (84, 118) 102 (90, 112) 99 (90, 117) 101 (85, 107) 106 (80, 112)
BMI, kg/m2 35 (30, 39) 33 (31, 38) 35 (31, 36) 33 (30, 36) 34 (27, 40)
Serum glucose, mg/dL 103 (90, 134) 99 (90, 114) 99 (89, 109) 98 (89, 113) 101 (94, 147)
Insulin, lIU/mL 14.3 (9.1, 23.8) 17.6 (10.4, 19.5) 16.7 (10.3, 22.0) 16.5 (11.5, 33.5) 18.7 (13.2, 27.8)
HOMA-IR 4.4 (2.1, 5.9) 3.9 (2.5, 4.9) 3.7 (2.5, 5.9) 3.8 (2.5, 9.34) 4.5 (3.2, 8.1)
Triglycerides, mg/dL 178 (124, 266) 175 (136, 224) 178 (113, 273) 146 (106, 184) 198 (171, 356)
ALT, U/L 88 (68, 123) 91 (70, 125) 80 (70, 122) 79 (71, 115) 84 (65, 140)
AST, U/L 49 (34, 79) 57 (38, 73) 51 (42, 68) 48 (39, 57) 60 (43, 114)
CK-18 fragments, U/L 583 (380, 879) 858 (360, 1339) 540 (430, 1235) 562 (402, 778) 639 (449, 1335)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK-18, cytokeratin-18; HOMA-IR, homeostasis model assessment of insulin resistance.
aOne subject who received 40 mg GS-9450 did not have a reported ethnicity.
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versus 2 (30) in the placebo group (Table 2). Reduc-
tions in ALT were most substantial in the group receiv-
ing 40 mg GS-9450, in which mean absolute ALT
values decreased from 106 U/L at baseline to 62 U/L
at week 4, and the proportion of subjects with normal
ALT increased from 0% at baseline to 35% at week 4
(Fig. 2).
Reductions in ALT occurred in a dose–response
manner, with the greatest activity observed with 40 mg
GS-9450 daily (Table 3). In a linear regression model,
the percent measurable change in ALT at week 4 versus
dose was highly signiﬁcant (P < 0.0001; Fig. 3). In
the 40-mg GS-9450 dose group, only two subjects
(8%) were nonresponders at week 4, meaning they
had a decrease in ALT of <10% relative to baseline.
The ALT reduction produced by GS-9450 was offset
within 1 week of stopping study medication and was
evident at the ﬁrst off-treatment follow-up visit. For
the 1-mg, 5-mg, and 10-mg dose groups, ALT levels
Table 2. Mean (SD in Parentheses) and Percent Changes in
ALT, AST, and CK-18 Fragments
Baseline
Change at
Week 2
Change at
Week 4
%Change at
Week 4
ALT, U/L
Placeboa 109 (76) 14 (80) 2 (30) 2 (29)
GS-9450
1 mgb 97 (44) 17 (31) 14 (40) 8 (41)
5 mgc 101 (38) 35 (18) 30 (26) 28 (21)
10 mgd 94 (38) 37 (23) 30 (26) 30 (20)
40 mge 106 (79) 46 (46) 47 (43) 43 (19)
AST, U/L
Placeboa 81 (58) 8 (63) 3 (27) 2 (42)
GS-9450
1 mgb 67 (46) 4 (36) 8 (35) 2 (41)
5 mgc 62 (31) 12 (16) 5 (24) 6 (38)
10 mgf 68 (46) 22 (34) 12 (36) 16 (29)
40 mge 57 (35) 16 (20) 13 (20) 20 (26)
CK&-18 fragments, U/L
Placebog 989 (820) 34 (545) 96 (619) 12 (73)
GS-9450
1 mgh 652 (380) 164 (384) 192 (584) 23 (81)
5 mgi 922 (691) 116 (608) 96 (641) 25 (120)
10 mgj 1035 (1147) 460 (866) 393 (723) 26 (38)
40 mgk 725 (655) 140 (490) 125 (212) 19 (32)
an ¼ 23 at baseline and 22 at week 4.
bn ¼ 26.
cn ¼ 26 at baseline and 25 at week 4.
dn ¼ 24 at baseline, 22 at week 2, and 23 at week 4.
en ¼ 25 at baseline, 24 at week 2, and 23 at week 4.
fn ¼ 24 at baseline and 22 at weeks 2 and 4.
gn ¼ 23 at baseline, 21 at week 2, and 23 at week 4.
hn ¼ 26 at baseline, 24 at week 2, and 25 at week 4.
in ¼ 26 at baseline, 25 at week 2, and 26 at week 4.
jn ¼ 24 at baseline, 23 at week 2, and 20 at week 4.
kn ¼ 25 at baseline, 24 at week 2, and 22 at week 4.
Fig. 2. Percent of subjects with normal ALT. After 4 weeks of treat-
ment, the GS-9450 40-mg group had the highest proportion of sub-
jects achieving ALT normalization, deﬁned as 43 U/L for males and
34 U/L for females. P values versus the placebo arm at 4 weeks of
treatment: P ¼ 0.07 for the 40-mg arm; P ¼ 0.41 for the 10-mg
arm; P ¼ 0.42 for the 5-mg arm; P ¼ 1 for the 1-mg group.
Table 3. Analysis of Covariance of ALT Changes From Baseline to Week 4a
Least Squares Means Difference
Statistical Model/Comparison GS-9450 (T) Placebo (R) T  R 95% CI P
Observed change from baseline to week 4 in ALT (U/L) using an ANCOVA model
40 mg GS-9450 vs. pooled placebo 43 4 39 (55, 23) <0.0001
10 mg GS-9450 vs. pooled placebo 32 4 28 (44, 12) 0.0007
5 mg GS-9450 vs. pooled placebo 29 4 25 (41, 9) 0.0019
1 mg GS-9450 vs. pooled placebo 15 4 11 (26, 4) 0.1595
Overall treatment <0.0001
Percent change from baseline to week 4 in ALT (U/L) using an ANCOVA model
40 mg GS-9450 vs. pooled placebo 42 2 40 (56, 24) <0.0001
10 mg GS-9450 vs. pooled placebo 31 2 28 (45, 12) 0.0006
5 mg GS-9450 vs. pooled placebo 28 2 26 (41, 10) 0.0017
1 mg GS-9450 vs. pooled placebo 8 2 6 (22, 10) 0.4539
Overall treatment <0.0001
aBaseline was deﬁned as the last available measurement before study drug administration. SAS PROC MIXED was performed with treatment and baseline as
ﬁxed effects. No adjustment was made for multiple comparisons. To protect family-wise type I error, for pairwise treatment comparisons involving placebo, GS-
9450 40, 10, 5, and 1 mg qd were compared sequentially. Mixed model covariance parameter estimates: rMSE, square root of mean square error.
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at follow-up weeks 2, 3, and 4 were similar to base-
line. For the GS-9450 40-mg group, mean ALT
change from baseline was 16 IU/L at follow-up week
2, 13 IU/L at follow-up week 3, and 12 IU/L at fol-
low-up week 4. In the placebo group, ALT levels
showed little change throughout treatment and follow-
up. No subject with a grade 3 ALT elevation upon dis-
continuation had a value higher than three times
baseline.
AST. Treatment with GS-9450 also resulted in
dose-dependent AST reductions. Across the GS-9450
treatment groups, AST levels decreased over the ﬁrst
week of treatment, with mean changes from baseline
ranging from 9 (23) to 27 (29) U/L. However, by
treatment week 4, mean (SD) changes in AST ranged
from 5 (24) to 13 (20) U/L in the GS-9450 treat-
ment groups versus 3 (27) in the placebo group.
The greatest mean change in AST at week 4 occurred
in the group receiving GS-9450 40 mg (Table 2). The
proportion of subjects with normal AST in the 40-mg
GS-9450 group increased from 20% at baseline to
48% at week 4, with a peak of 77% at day 3. Mean
AST increased to modestly above baseline levels in all
GS-9450 treatment groups within 1 week of stopping
study medication.
Cytokeratin-18 Fragments. CK-18 fragment values
declined in the two highest GS-9450 dose groups
(Table 2): for the 10-mg group, mean (SD) change
from baseline to week 4 was 393 (723) U/L, and for
the 40-mg group, the mean (SD) change was 125
(212) U/L. However, the differences between each of
the GS-9450 groups (40, 10, 5, and 1 mg) and pla-
cebo for the absolute and percent changes from base-
line at week 4 were not signiﬁcant (P > 0.05 for all
comparisons).
Additional Biomarkers. Treatment with GS-9450
did not have obvious effects on markers of insulin re-
sistance. Median changes from baseline to week 4 for
GS-9450 1 mg, 5 mg, 10 mg, 40 mg and placebo,
respectively, were as follows: serum glucose 0.5, 5,
12, 0, 6 mg/dL; insulin 3.13, 3.55, 2.21, 1.68,
2.23 lIU/mL; HOMA-IR 1.07, 0.82, 0.71, 0.35,
1.48; triglyceride 0, 28, 3, 7, 5 mg/dL; high-
density lipoprotein 1, 2, 2, 2, 2 mg/dL; and
c-glutamyl transpeptidase 3, 8, 3, 4, 3 U/L.
During the 4-week trial period, median body weight
within each treatment group was unchanged.
Pharmacokinetic and Pharmacodynamic
Assessments
Under fasting conditions, GS-9450 reached peak
plasma concentrations in approximately 2-3 hours
(median Tmax). Multiple-dose median T1/2 values
ranged between 13 and 14 hours. GS-9450 Cmax was
dose-proportional from 1 to 40 mg. Mean predose
and 24-hour postdose and GS-9450 concentrations
indicated that steady state had been reached by 2-4
weeks of daily dosing in all dose groups (Fig. 4).
Exploratory pharmacokinetic and pharmacodynamic
modeling revealed that inhibitory Emax models pro-
vided best ﬁt of GS-9450 exposure for differences
between time-weighted averages at week 4 in ALT and
CK-18 fragments. For the week 4 difference in ALT or
CK-18 fragments, the mean exposure produced with
40 mg GS-9450 appeared to mediate a response at
least 82% of the maximal effect achievable with GS-
9450.
Safety Assessments
The frequency of treatment-emergent AEs during
the 4-week on-treatment period was 77% for the GS-
9450 1-mg group, 85% for the GS-9450 5-mg group,
75% for the GS-9450 10-mg group, 80% for the GS-
9450 40-mg group, and 57% for the placebo group.
The most common AEs (occurring in  6 subjects
[5%] overall) during the on-treatment period were
diarrhea, nausea, abdominal pain upper, abdominal
pain, dyspepsia, fatigue, arthralgia, back pain, and
headache (Table 4). Most treatment-emergent AEs
were considered by the investigator to be of mild or
moderate intensity. Treatment-emergent severe AEs
included abscess, type 2 diabetes mellitus, back pain,
arthralgia, osteoarthritis, pain in the extremity, and
Fig. 3. Percent measurable change of ALT at week 4. In a linear
regression of percent measurable change in ALT levels (change from
baseline/[baseline  20 U/L]), the percent measurable change at
week 4 versus dose was highly signiﬁcant (P < 0.0001). An outlier
value of 600 for percent measurable change of ALT at week 4 was
excluded from the assessments.
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carpal tunnel syndrome. All of these events were con-
sidered to be unrelated to study drug, except for the
event of pain in the extremity.
There were no deaths reported during the study.
There were no serious AEs (SAEs) during the on-treat-
ment period of the study; however, three SAEs were
reported off-treatment by two subjects. One subject
who received 1 mg GS-9450 had two episodes of pan-
creatitis, both of which resolved and were considered
unrelated to study drug; this subject had a history of
multiple prior episodes of pancreatitis and a history of
dilatation and stenting of the sphincter of Oddi. One
subject in the GS-9450 10-mg group developed hypo-
thyroidism that occurred after study completion and
database lock. This event was reported as related to
study drug. In retrospect, high-titer antithyroglobulin
antibody levels were found in screening and baseline
samples.
One subject, taking GS-9450 40 mg, left the study
because of a treatment-related AE of moderate facial
ﬂushing that started on day 1. This subject received
her last dose of study drug on day 9, and the event
resolved on day 25.
The percentage of subjects with at least one treat-
ment-emergent grade 3 or 4 laboratory abnormality
ranged from 12% to 17% across the GS-9450
Fig. 4. Mean (SD) steady-state
GS-9450 concentration-versus-time
proﬁles. GS-9450 was quantiﬁable
over the dosing interval for all treat-
ment groups. Examination of the mean
and median GS-9450 trough values
and mean predose and 24-hour post-
dose concentrations achieved during
serial pharmacokinetic assessment for
each group indicated that steady state
had been reached by 2-4 weeks of
daily dosing.
Table 4. Adverse Events (AEs) Occurring During Treatment
Adverse Events, n (%) GS-9450 1 mg (n ¼ 26) 5 mg (n ¼ 26) 10 mg (n ¼ 24) 40 mg (n ¼ 25) Placebo (n ¼ 23)
No. of subjects with at least one AE 20 (77) 22 (85) 18 (75) 20 (80) 13 (57)
Total no. of events 62 64 67 60 48
Gastrointestinal disorders
Diarrhea 2 (8) 6 (23) 6 (25) 5 (20) 2 (9)
Nausea 3 (12) 1 (4) 3 (13) 3 (12) 1 (4)
Abdominal pain upper 1 (4) 1 (4) 4 (17) 1 (4) 0
Abdominal pain 1 (4) 2 (8) 1 (4) 1 (4) 1 (4)
Dyspepsia 2 (8) 2 (8) 1 (4) 1 (4) 0
Constipation 2 (8) 0 0 2 (8) 1 (4)
Dry mouth 1 (4) 0 2 (8) 1 (4) 0
Gastroesophageal reﬂux disease 0 0 0 3 (12) 1 (4)
General disorders and administration site conditions
Fatigue 6 (23) 5 (19) 2 (8) 2 (8) 5 (22)
Asthenia 1 (4) 1 (4) 1 (4) 0 1 (4)
Infections and infestations
Nasopharyngitis 2 (8) 0 0 2 (8) 1 (4)
Musculoskeletal and connective tissue disorders
Arthralgia 1 (4) 3 (12) 1 (4) 3 (12) 0
Back pain 1 (4) 2 (8) 0 1 (4) 2 (9)
Pain in extremity 1 (4) 0 1 (4) 2 (8) 0
Nervous system disorders
Headache 4 (15) 7 (27) 4 (17) 4 (16) 5 (22)
Dizziness 2 (8) 0 0 2 (8) 1 (4)
Somnolence 1 (4) 2 (8) 0 0 0
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treatment groups and was 35% in the placebo group.
Treatment-emergent grade 3 or 4 laboratory abnormal-
ities that occurred in more than one subject during the
on-treatment period in the overall study included ele-
vated ALT (all grade 3: one subject in the 1-mg group,
two subjects on placebo), elevated AST (one grade 4
associated with elevated creatine kinase in the 1-mg
group; grade 3 in three placebo subjects, one subject
in the 5- and two in the 10-mg group), elevated serum
lipase (one subject in the 5-mg group, one in placebo),
and elevated serum glucose, urine blood, and urine
glucose. No subjects had total bilirubin values  2
mg/dL concurrently with grade 3 or 4 ALT or AST
abnormalities. One subject receiving 40 mg GS-9450
had an isolated grade 3 bilirubin value (3.1 mg/dL) at
week 2, but this value was similar to screening, and
subsequent levels were at or below pretreatment. None
of these grade 3-4 laboratory abnormalities resulted in
discontinuation of study drug treatment. Overall, there
was no clearly evident on-treatment pattern of clini-
cally relevant changes in laboratory assessments or spe-
ciﬁc laboratory abnormalities observed following 4
weeks of treatment with GS-9450.
Discussion
This study provides evidence that apoptosis inhibi-
tion results in biochemical improvement in amino-
transferase values in subjects with NASH, a highly
prevalent disease with no established, effective pharma-
cological therapy. Four weeks of daily dosing with a
selective caspase inhibitor, GS-9450, resulted in signiﬁ-
cant, dose-dependent reductions in ALT. The highest
reductions occurred in the 40-mg group, with one
third of treated subjects experiencing ALT normaliza-
tion over the treatment interval. This reduction in
ALT levels occurred as early as the third day of treat-
ment, which suggests that inhibition of apoptosis may
be directly linked to lower ALT levels. The reduction
in ALT was maintained throughout dosing. In contrast,
ALT values were stable in subjects who received pla-
cebo. In the highest GS-9450 dose group, only two
patients were nonresponders, thus suggesting a strong
effect of the drug in most exposed individuals with
NASH. A linear regression analysis of percent measur-
able change in ALT levels versus dose was statistically
signiﬁcant for all on-treatment weeks tested (P <
0.0001 for week 4).
This analysis suggests that a robust reduction in
ALT levels can be achieved regardless of the baseline
ALT level. The ALT values returned to pretreatment
levels or higher on discontinuation of the drug. Similar
posttreatment ALT increases have been documented
with another pancaspase inhibitor in HCV-infected
subjects.12 This suggests that long-term treatment is
necessary for maintained beneﬁt, and therefore a care-
ful assessment of long-term safety will be crucial in
future trials.
The therapeutic value of an anticaspase in humans
was ﬁrst evaluated with IDN-6556, a broad-spectrum,
irreversible, speciﬁc caspase inhibitor that blocks Fas-
induced apoptosis in vitro and in animal models.13,14
A 14-day treatment regimen in subjects with a variety
of chronic liver diseases, mostly chronic hepatitis C,
resulted in 31%-59% reductions in ALT without a
clear dose–effect relationship.15 Only ﬁve subjects had
NASH, and ALT reduction in these few subjects was
reported to reach 59%. The results in subjects with
HCV infection were subsequently conﬁrmed in a
larger study in which a consistent reduction in ALT ac-
tivity, ranging from 36% to 46%, was apparent after
only 1 week of administration.12 However, no results
are available for a larger cohort of patients with
NASH.
It is tempting to speculate that reduction in ALT
levels reﬂects improvement in liver injury. The latter
can only be deﬁned histologically, but some data indi-
cate that ALT is a valid proxy for evaluating improve-
ment in hepatic necroinﬂammation. In liver diseases
such as HBV or HCV infection or autoimmune hepa-
titis, successful treatment results in a signiﬁcant reduc-
tion in ALT levels. Drugs that have shown some histo-
logical efﬁcacy in NASH also reduced ALT levels.16–19
In a study that compared 2 years of treatment with
ursodeoxycholic acid (UDCA) to placebo, rates of
ALT change during treatment were signiﬁcantly corre-
lated with changes in inﬂammation but not steatosis
or ﬁbrosis.20 ALT changes alone predicted histologic
improvement or worsening, as shown by area under
the receiver operating characteristic curves (0.72-
0.77).20 Therefore, the current trial, which demon-
strates a strong and sustained ALT reduction, suggests
that GS-9450 may improve hepatic injury, although
this will need to be tested in larger, longer term
studies.
Experimental studies have shown that pancaspase
inhibitors such as VX-166 reduce hepatocyte apopto-
sis, hepatocellular damage (ALT levels), and oxidative
stress.21 A signiﬁcant improvement in hepatic inﬂam-
mation was observed as the overall NAS activity score
declined together with a reduction in TNF-a and
monocyte chemoattractant protein 1 (MCP1) hepatic
expression, two potent proinﬂammatory and chemo-
tactic cytokines.21 Additionally, in some experimental
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conditions, pancaspase inhibition with VX-166 was
able to block ﬁbrogenesis, as evidenced by a reduction
in collagen deposition and in a-smooth-muscle actin,
collagen, and hydroxyproline expression in the liver.22
CK-18 (the M30 fragment) has been proposed as a
serum marker of hepatocyte apoptosis in both
NASH23,24 and HCV.25 In a group of 139 subjects
with biopsy-proven nonalcoholic fatty liver disease
(NAFLD) and 150 controls, CK-18 fragments pre-
dicted histological NASH.26 However, patients with
steatosis alone, despite increased apoptosis, had similar
CK-18 levels as controls.26 Another study reported an
insufﬁcient sensitivity and speciﬁcity of CK-18 alone
for the diagnosis of steatohepatitis.27 Moreover, CK-18
levels were correlated not only with steatohepatitis but
also with overall severity of liver disease, in particular
the stage of ﬁbrosis,26 which strongly suggests that
other aspects of liver injury might confound its diag-
nostic accuracy toward NASH. Collectively, these data
suggest that the relationship between the extent of ap-
optosis and CK-18 levels may be confounded by other
aspects of liver injury. In the current study, although
values of CK-18 fragments decreased in response to
GS-9450 treatment in the two highest dose groups,
the sensitivity of this experimental marker was insufﬁ-
cient in the short term to discern a dose–response rela-
tionship manifestly evident by ALT response.
Long-term use of antiapoptotic agents raises the the-
oretical concern of increased risk of neoplastic transfor-
mation. Although this possibility must be carefully
addressed in future investigations of this class of drugs,
several factors suggest that the risk may not be
increased. GS-9450 is preferentially concentrated in
the liver; therefore, exposure of other organs should be
considerably reduced. GS-9450 is not a pancaspase but
rather a selective caspase inhibitor, which does not
directly block caspase-3 activity or the endogenous
pathway of apoptosis. Residual apoptotic activity is
allowed to proceed. Moreover, the simple view that
abrogating apoptosis will result in a higher incidence
of tumors has been challenged.28
Mice lacking myeloid cell leukemia-1, a survival fac-
tor from the Bcl-2 family, have increased apoptosis,
which translates into development of malignant HCC-
like lesions.29 In these mice, HCC formation is
observed in the background of ﬁbrosis but in the ab-
sence of apparent inﬂammatory responses, thus indi-
cating that liver carcinogenesis is promoted by
enhanced and ‘‘clean’’ apoptosis.28 Several explanations
may account for this apparent paradox. An increased
apoptotic environment correlates with elevated hepatic
proliferation,29 possibly related to nonapoptotic func-
tions of caspases such as cellular activation, prolifera-
tion, or differentiation.30,31 Increased apoptosis might
also result in up-regulation of surviving,29 a molecule
highly expressed in numerous cancers and involved in
cell cycle progression and proliferation.32 These data
suggest that whereas physiologic apoptosis helps pro-
tect from cancer, excessive apoptosis might, at least in
some experimental situations, enhance neoplastic
transformation.
Extrapolation of these intriguing ﬁndings to human
disease states is, at this point, speculative. In the cur-
rent trial we excluded subjects with cirrhosis, a preneo-
plastic state, because they are at high risk for malig-
nant transformation. Safety data on long-term
exposure to antiapoptotic agents should be obtained
before further antiapoptotic agents are considered as
valid longer term treatment strategies for liver disease
patients.
In this study we did not detect any effect of anti-
caspase treatment on surrogate markers of insulin re-
sistance or on parameters associated with the metabolic
syndrome (glucose, insulin, and lipid measurements).
This is not unexpected, as inhibiting hepatocyte apo-
ptosis should result in a direct hepatoprotective effect
with no apparent insulin-sensitizing potency.33 Other
antiapoptotic agents might have additional beneﬁcial
effects on insulin resistance, thus widening the interest
of this class of agents for the treatment of NASH. For
instance, recent data have shown that the proapoptotic
receptor Fas is up-regulated in adipose tissue of obese
and diabetic patients, in whom it can mediate inﬂam-
matory pathways.34 Abrogating Fas expression speciﬁ-
cally in adipose tissue of mice fed a high-fat diet pre-
vented whole-body and adipose tissue insulin
resistance and protected the animals against hepatic
steatosis.34 Whether antiapoptotic agents administered
for a longer duration could reproduce these effects
needs to be further tested and, if conﬁrmed, could be
a particularly exciting development for the treatment
of NASH.
In this trial GS-9450 was safe and well tolerated; no
adverse event types occurred more frequently with GS-
9450 than placebo. No treatment-emergent grade 3 or
4 ALT elevations were observed in any of the 75
patients during dosing with 5, 10, or 40 mg GS-9450
daily. However, in a larger, 6-month study in hepatitis
C subjects, episodes of drug-induced liver injury at-
tributable to GS-9450 occurred, and the trial was ter-
minated early.
In summary, in this proof-of-principle, randomized,
placebo-controlled trial, 4 weeks of treatment with the
GS-9450 selective caspase inhibitor resulted in
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signiﬁcant declines in ALT levels and smaller nonstatis-
tically signiﬁcant reductions in AST and CK-18 frag-
ments in patients with NASH. This ﬁnding suggests
that reducing apoptosis may be a valuable therapeutic
strategy in patients with NASH. Safe and effective
antiapoptotic agents should therefore be considered for
further clinical evaluation in this disease.
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